Skip to main content

Table 3 Comparison of the progression-free survival and overall survival between groups at the final follow-up

From: Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Variable

CAP-B (n = 130)

CAP (n = 133)

P- value

Median progression-free survival (mos)

11.5 ± 5.93

9.2 ± 7.61

0.013*a

Median overall survival (mos)

16.2 ± 7.02

12.4 ± 6.52

0.022*a

Progression-free survival rate

29.2%

16.5%

0.014*b

Overall survival rate

50.8%

36.1%

0.016*b

  1. *Statistically significant values. aAnalysed using the independent-samples t-test. bAnalysed using the Kaplan-Meier method. CAP-B capecitabine plus bevacizumab, CAP capecitabine
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us